Showing 881 - 900 results of 21,342 for search '(( significant ((co decrease) OR (nn decrease)) ) OR ( significant decrease decrease ))', query time: 0.39s Refine Results
  1. 881
  2. 882
  3. 883
  4. 884
  5. 885

    Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i> by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…The seroprevalence did not significantly decrease following DA treatment. These results include all individuals sampled, irrespective of whether they took the medications. …”
  6. 886

    NIE ELISA results. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
  7. 887

    Kato Katz and PCR database 12 months collection. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
  8. 888

    Master database baseline, 4 weeks and 1 year. by Jannet A. Tobon Ramos (20855642)

    Published 2025
    “…<div><p>Background</p><p>Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). …”
  9. 889
  10. 890
  11. 891
  12. 892
  13. 893
  14. 894
  15. 895
  16. 896
  17. 897

    Flow chart. by Myriam Aïche (22290591)

    Published 2025
    Subjects:
  18. 898
  19. 899
  20. 900